Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zoll discusses GE/Cardiac Science deal

This article was originally published in The Gray Sheet

Executive Summary

While "GE has been in the defibrillation business a few times," Zoll Medical CEO Richard Packer says the firm "never really goes at it with full force" as "they see [defibrillation] as complimentary" to their business, rather than "necessary." The exec's comments, which came June 15 at a Thomas Weisel conference, responded to a question about whether Zoll expected to feel any impact from Cardiac Science's recently inked North American distribution agreement with GE Healthcare for the PowerHeart ECD defibrillator (1"The Gray Sheet" May 9, 2005, p. 25). Zoll manufacturers the LifeVest defibrillator...

You may also be interested in...

Cardiac Science To Challenge Philips As Sole Biphasic AED Player In Japan

Cardiac Science anticipates receiving approval from the Japanese Ministry of Health, Labour & Welfare for a biphasic automated external defibrillator by the end of Q2, the firm says

Resolving Botanicals Deadlock 'Not A Priority' For European Commission

Tensions between industry and the European Commission on the issue of  health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future. 

Hikma’s Vascepa Launch Strategy ‘Can Cause Market Confusion’

Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts